Innovative Eyewear (NASDAQ:LUCY) & ICU Medical (NASDAQ:ICUI) Head to Head Survey

Innovative Eyewear (NASDAQ:LUCY) and ICU Medical (NASDAQ:ICUI) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Volatility & Risk

Innovative Eyewear has a beta of 2.75, meaning that its share price is 175% more volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500.

Profitability

This table compares Innovative Eyewear and ICU Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Innovative Eyewear	-225.26%	-88.90%	-80.34%
ICU Medical	2.76%	8.46%	4.49%

Valuation & Earnings

This table compares Innovative Eyewear and ICU Medical”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innovative Eyewear	$2.66 million	2.70	-$7.59 million	($1.29)	-0.64
ICU Medical	$2.23 billion	1.93	$730,000.00	$2.39	72.01

ICU Medical has higher revenue and earnings than Innovative Eyewear. Innovative Eyewear is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Innovative Eyewear and ICU Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innovative Eyewear	1	1	0	0	1.50
ICU Medical	0	3	4	2	2.89

ICU Medical has a consensus price target of $195.20, indicating a potential upside of 13.42%. Given ICU Medical’s stronger consensus rating and higher probable upside, analysts clearly believe ICU Medical is more favorable than Innovative Eyewear.

Institutional & Insider Ownership

1.0% of Innovative Eyewear shares are owned by institutional investors. Comparatively, 96.1% of ICU Medical shares are owned by institutional investors. 1.8% of Innovative Eyewear shares are owned by company insiders. Comparatively, 2.1% of ICU Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

ICU Medical beats Innovative Eyewear on 13 of the 15 factors compared between the two stocks.

About Innovative Eyewear

Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. In addition, the company launches an application, Lucyd app for iOS/Android users. It sells its products through various e-commerce, and retail store and distribution channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. is a subsidiary of Lucyd Ltd.

About ICU Medical

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.